Bradley Foster & Sargent’s Praxis Precision Medicines PRAX Stock Holding History

Bradley Foster & Sargent’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-733	Closed	-$112K	–	462
2022 Q1	$112K	Hold	733	–	–	﹤0.01%	462
2021 Q4	$217K	Hold	733	–	–	﹤0.01%	426
2021 Q3	$203K	Hold	733	–	–	﹤0.01%	403
2021 Q2	$201K	Buy	733 +266	+57%	+$95.3K	﹤0.01%	392
2021 Q1	$229K	Hold	467	–	–	0.01%	356
2020 Q4	$385K	Buy	+467	New	+$273K	0.01%	315

Other funds holding PRAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bradley Foster & Sargent's PRAX Position: Q2 2022 in Review

Bradley Foster & Sargent sold out of Praxis Precision Medicines (PRAX) in Q2 2022, closing a stake of 733 shares — an estimated $112K sold.

Bradley Foster & Sargent first reported a position in PRAX in Q4 2020 and held it in 6 quarters. The position peaked at $385K in Q4 2020. 95 funds tracked by Wall St. Rank hold PRAX as of Q2 2022.

Bradley Foster & Sargent reported no remaining Praxis Precision Medicines position as of Q2 2022 after selling out during the quarter.
Bradley Foster & Sargent sold 733 Praxis Precision Medicines shares in Q2 2022, an estimated $112K.
Bradley Foster & Sargent first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 6 quarters.
Bradley Foster & Sargent's Praxis Precision Medicines position peaked at $385K in Q4 2020.
95 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2022.

Based on Bradley Foster & Sargent's 13F filing for Q2 2022, filed 11 Aug 2022.